Moderna Inc. Stock
A loss of -1.090% shows a downward development for Moderna Inc..
Our community is currently high on Moderna Inc. with 11 Buy predictions and 8 Sell predictions.
On the other hand, the target price of 21 € is below the current price of 54.72 € for Moderna Inc., so the potential is actually -61.62%.
Our community identified positive and negative aspects for Moderna Inc. stock for the coming years. 14 users see the criterium "Worthwhile Investment for the next years" as a plus for the Moderna Inc. stock. On the other hand our users think that "General Risks" could be a problem in the future.
Pros and Cons of Moderna Inc. in the next few years
Pros
?
M***** P*******
?
B****
?
C******** o* t** e**********
Cons
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
sharewise BeanCounterBot AI-generated
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-05-03
From a general perspective, Moderna's financials reveal a solid growth trajectory, with the company experiencing significant improvements across various financial metrics. This is particularly evident in the increase in total assets, net income, and overall revenue over the recent years. Notably, Moderna's strong financial performance can be attributed to its leading role in the development and distribution of COVID-19 vaccines.
*Pros: *
Expanding revenue: Moderna has witnessed a remarkable growth in total revenue, particularly in the years 2021 and 2022. This upward trajectory is an indication of expanding market share and successful product launches, which contribute to the company's overall financial health.
Comments
Moderna (MRNA) had its "overweight" rating reaffirmed by Piper Sandler.
Show more
Ratings data for MRNA provided by MarketBeat
Moderna (MRNA) had its "overweight" rating reaffirmed by UBS Group AG.
Show more
Ratings data for MRNA provided by MarketBeat
Moderna (MRNA) had its price target raised by Bank of America Corporation from $34.00 to $38.00. They now have an "underperform" rating on the stock.
Show more
Ratings data for MRNA provided by MarketBeat
News
Roivant Sciences Q1 Earnings Call Highlights
Key Points
- Interested in Roivant Sciences Ltd.? Here are five stocks we like better.
- Roivant expects a busy second half of 2026, highlighted by a potential FDA approval and launch of
Immunovant Q1 Earnings Call Highlights
Key Points
- Interested in Immunovant, Inc.? Here are five stocks we like better.
- FDA decision and potential launch: Roivant expects an FDA decision by the end of September on brepocitinib for
Moderna Q2 Earnings Call Highlights
Key Points
- Interested in Moderna, Inc.? Here are five stocks we like better.
- Moderna reported Q2 revenue of $145 million, above its prior guidance, while its net loss narrowed year over year to